AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

The European Commission (EC) has granted marketing authorisation for Sandoz ‘s Afqlir, a biosimilar to the reference medicine ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.

During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically ...

At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving ...

The FDA has released final draft recommendations for using real-world data and evidence in drug development.

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...

The Danish infectious disease specialist has $340m (DKK 2.4m) lined up through orders for its MVA-BN vaccine known under the ...